[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

$gpcr

$GPCR is gaining attention with positive sentiment, but investors are watching for the next move regarding safety and potential acquisition. The company's lead drug is under scrutiny, with the market focused on its safety profile and potential for big pharma acquisition, which could drive the price up or down in the coming hours.

About $gpcr

A pharmaceutical company focused on developing novel therapeutics, particularly in the area of GLP-1 receptor agonists for metabolic diseases.

Engagements: XXXXX #

Engagements Line Chart
Engagements 24-Hour Time-Series Raw Data
Current Value: XXXXX
Daily Average: XXXXXX
1 Week: XXXXXX +0.60%
1 Month: XXXXXXX -XX%
1-Year High: XXXXXXX on 2025-06-25
1-Year Low: XX on 2025-09-14

Social Network	X
Engagements	XXXXX

Mentions: XX #

Mentions Line Chart
Mentions 24-Hour Time-Series Raw Data
Current Value: XX
Daily Average: XX
1-Year High: XXX on 2025-08-22
1-Year Low: X on 2025-09-14

Social Network	X
Mentions	XX

Creators: XX #

Creators Line Chart
Creators 24-Hour Time-Series Raw Data
XX unique social accounts have posts mentioning $gpcr in the last XX hours which is no change from in the previous XX hours Daily Average: XX
1-Year High: XXX on 2025-06-27
1-Year Low: X on 2025-09-14

The most influential creators that mention $gpcr in the last XX hours

Creator	Rank	Followers	Posts	Engagements
@PersimmonTI	X	XXXXXX	X	XXX

Sentiment: XXX% #

Sentiment Line Chart
Sentiment 24-Hour Time-Series Raw Data
Current Value: XXX%
Daily Average: XX%
1 Week: XXX% no change
1 Month: XXX% +50%
1-Year High: XXX% on 2025-05-13
1-Year Low: XX% on 2025-10-05

Most Supportive Themes

GLP-1 Therapy Benefits: (45%) Posts highlight the positive impacts of GLP-1 therapy, including weight loss, improved health markers, and reduced risks in various conditions.
Positive Sentiment on $GPCR: (25%) Several posts express optimism about $GPCR's potential, particularly regarding its CEO, technicals, and market opportunity.
Broader GLP-1 Market Discussion: (15%) Discussions about the broader GLP-1 market, including comparisons with competitors like $LLY and $NVO, and the potential for acquisitions.

Most Critical Themes

Safety Concerns and Side Effects: (10%) Mentions of potential side effects and safety concerns associated with GLP-1 therapies, including risks like gallbladder issues and psychiatric concerns.
Comparison to Competitors: (5%) Comparisons to competitors like $LLY and $MTSR, with some questioning $GPCR's efficacy and potential for success.

Network engagement breakdown:

Network	Positive	%	Neutral	%	Negative	%
X	XXX	X%	XXX	XX%	X	X%

Total	XXX	X%	XXX	XX%	X	X%

Top assets mentioned In the posts about $gpcr in the last XX hours

Metsera, Inc. Common Stock (MTSR) Viking Therapeutics, Inc (VKTX) Pfizer, Inc. (PFE) Dyne Therapeutics, Inc. Common Stock (DYN) Bitcoin Incognito (XBI) Dyne Therapeutics, Inc. Common Stock (DYN) Novo-Nordisk (NVO) Agios Pharmaceuticals, Inc. (AGIO) Merck & Co., Inc. (MRK) Cytokinetics Inc. (CYTK)

Top topics mentioned In the posts about $gpcr in the last XX hours

stocks healthcare, $mtsr, $vktx, $pfe, dyne therapeutics, $xbi, $psnl, $dyn, $nvo, $elvn, $agio, stocks bitcoin treasuries, $mrk, $cytk, behind the, $wves, gsk plc, $gsk, $atxs, $cnc, $elv, $unh, lets go, $bbc, $janx, pakistani rupee, eli lilly, investment, $200m2b, $bwb, $ante, fold holdings, $drug, $ewtx, $crml, $cenx, $ag, $uamy, $cde, $sedg, $hond, $leu, $csiq, $smr, $cdtx, $dhr, $pcsa, $mrna, $bntx, $nuvb, acquisition, superrare, superrarebears, coins solana ecosystem, coins dao, stocks bitcoin miners, stocks crypto treasuries, $hive, $clsk, $jade, $kros, $rapt, $tdoc, $beam, hims hers, $azn, $amgn, $supn, upside

Top Social Posts #

Top posts by engagements in the last XX hours

Showing only X posts for non-authenticated requests. Use your API key in requests for full results.

"Category Overview of stocks I track: Crypto: +2.08%; XX of XX Up (=4%: $WULF $HIVE $IREN $CLSK $BITF) Clean Energy: +2.05%; XX of XX Up (=4%: $CSIQ $SEDG $ARRY $NXT $SMR $HOND $RUN) Bio/Pharm: +1.04%; XX of XXX Up (=4%: $NGNE $SGMT $ORKA $APGE $CDTX $RLAY $GLUE $CGON $AQST $GPCR $AMLX $ZBIO $QURE $MGTX $SRRK $TNGX $MENS $PHAT $RNA $IMTX $MLYS $ABVX $UPB $CMPX $NTLA) Fuel/Elec/Util: +0.83%; XX of XX Up (=4%: $UUUU $ALNT $BW $EAF $AREC $NRGV) Semis: +0.61%; XX of XX Up (=4%: $LAES $WOLF $RGTI $CEVA) (1 of 2)"
X Link @Brad_E_Schulz 2025-10-09T21:23Z 17.6K followers, 1098 engagements

"Category Overview (as of 11:55amEST): Clean Energy: +2.10%; XX of XX Up (=4%: $SEDG $HOND $LEU $CSIQ $SMR $RUN $NXT) Fuel/Elec/Util: +1.44%; XX of XX Up (=4%: $UUUU $ALNT $BW $PSIX $EAF $AREC $AMPX) Bio/Pharm: +1.29%; XXX of XXX Up (=4%: $SGMT $NGNE $APGE $PHAT $KRRO $NTLA $AQST $GLUE $ZBIO $CDTX $RLAY $CGON $QURE $ORKA $ABVX $MGTX $SUPN $SRRK $COGT $AMLX $BEAM $GPCR) Telcom/Media: +0.29%; X of XX Up (=4%: $ASTS) Oil&Gas: +0.12%; XX of XX Up Healthcare: +0.08%; XX of XX Up (=4%: $BKD $WGS $INMD $BBNX $AIRS) (1 of 2)"
X Link @Brad_E_Schulz 2025-10-09T15:59Z 17.6K followers, XXX engagements

"Category Overview (as of 11:35amEST): Materials: +2.74%; XX of XX Up (=5%: $CRML $CENX $AG $UAMY $CDE $HYMC $FSM $SLI $HBM $MUX $GROY $SBSW $ALM $IDR $ERO $MT $BVN $VZLA $SCCO $EQX) Bio/Pharm: +2.45%; XXX of XXX Up (=5%: $NTLA $IMAB $NGNE $SLDB $APGE $PRME $CADL $EDIT $RGNX $ABSI $SANA $CRSP $KURA $MESO $CGON $FDMT $SEPN $BEAM $RCUS $OCUL $EYPT $STOK $RVMD $GPCR $SRRK $OLMA $CLDX $IMTX) (1 of 2)"
X Link @Brad_E_Schulz 2025-10-08T15:38Z 17.6K followers, XXX engagements

"$VKTX remains my primary investment in the obesity space besides $LLY and small $GPCR Lot of folks shaken out post oral data. Stock slowly regaining momentum post $MTSR acquisition in the obesity space. Huge space for multiple players to co-exist and take a slice from the obesity TAM"
X Link @Pharmdca 2025-10-08T15:33Z 109.1K followers, 14.7K engagements